Goldman Sachs raised its forecast for the global obesity-drug market to $114bn by 2030, up roughly 13% from a $101bn projection in December, citing rapid adoption of oral GLP-1 obesity drugs and a shift from a niche, high-price segment to a mass-cons

2026-06-09

Goldman Sachs raised its forecast for the global obesity-drug market to $114bn by 2030, up roughly 13% from a $101bn projection in December, citing rapid adoption of oral GLP-1 obesity drugs and a shift from a niche, high-price segment to a mass-consumer market.